Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Niki BioSolutions Inc is a clinical-stage life sciences company focused on unmet medical needs and providing genomic and biomarker testing solutions to healthcare providers, research institutions, and life sciences organizations. Its activities include the development and application of proprietary technologies to support precision medicine across therapeutic areas including brain health and oncology. The company also collaborates with academic centers, disease foundations, and biopharmaceutical companies.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
View stock

Stock highlights

Stock comparison highlights
Stock name
Niki BioSolutionsAbbVie
Last price
$1.70$294.45
Currency
USD
USD
$4.6M$521B
-50.79
-$2.86$5.81
-0.830.19
0$6.83
02.35%
Sector
HealthHealth
Employees
-57,000
Ticker
$NIKI$ABBV
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $NIKI or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.